The actions of phloridzin on sodium ion transporters and potential difference in nasal airway epithelium.
| ISRCTN | ISRCTN84503991 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN84503991 |
| Secondary identifying numbers | N0236143719 |
- Submission date
- 30/09/2005
- Registration date
- 30/09/2005
- Last edited
- 05/04/2011
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Emma Baker
Scientific
Scientific
St George's Hospital
University of London
Cranmer Terrace
Tooting
London
SW17 0RE
United Kingdom
| Phone | +44 (0)20 8725 5383 |
|---|---|
| ebaker@sgul.ac.uk |
Study information
| Study design | In vivo pharmacological study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Other |
| Study setting(s) | Not specified |
| Study type | Not Specified |
| Scientific title | |
| Study objectives | To determine whether nasal application of phloridzin, a sodium-glucose co-transporter (SGLT-1) inhibitor, alters nasal potential difference demonstrating SGLT-1 function. |
| Ethics approval(s) | Wandsworth REC (UK) |
| Health condition(s) or problem(s) studied | Respiratory: Chronic obstructive pulmonary disease (COPD) |
| Intervention | Nasal potential difference: between the 'sensing' electrode in contact with the nasal epithelium, and the 'reference' electrode, a butterfly needle inserted under the skin of the forearm, is measured. Phloridzin in Ringer's solution will then be additionally perfused onto the nasal epithelium and any further change in nasal PD recorded. On a second visit a repeat of the above protocol will be carried out with phloridzin followed be amiloride. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | phloridzin |
| Primary outcome measure | Changes in the measured nasal potential difference with phloridzin |
| Secondary outcome measures | No secondary outcome measures |
| Overall study start date | 01/10/2002 |
| Completion date | 01/12/2007 |
| Reason abandoned (if study stopped) | Not a clinical trial |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | 10 |
| Key inclusion criteria | Healthy, non-smoking volunteers with normal nasal mucosa and random plasma glucose <7mmol/l. |
| Key exclusion criteria | 1. Nasal disease 2. Diabetes mellitus 3. Pregnancy |
| Date of first enrolment | 01/10/2002 |
| Date of final enrolment | 01/12/2007 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
St George's Hospital
London
SW17 0RE
United Kingdom
SW17 0RE
United Kingdom
Sponsor information
Department of Health
Government
Government
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
| Phone | +44 (0)20 7307 2622 |
|---|---|
| dhmail@doh.gsi.org.uk | |
| Website | http://www.dh.gov.uk/Home/fs/en |
Funders
Funder type
Government
St George's Healthcare NHS Trust (UK)
No information available
No External Funding
No information available
NHS R&D Support Funding
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
